Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway

Clinical and Experimental Immunology

Volumn 178, Issue 3, 2014, Pages 548-560

  Kyriakidis, N C ^a   Kapsogeorgou, E K ^a   Gourzi, V C ^a   Konsta, O D ^a   Baltatzis, G E ^a   Tzioufas, A G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ro52 TRIM21 autoantigen; Salivary gland epithelial cells; Sj gren's syndrome; TLR 3; Type I interferons

Indexed keywords

BETA INTERFERON; INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; RIBONUCLEOPROTEIN; SS-A ANTIGEN; TLR3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 3;

APOPTOSIS; BIOSYNTHESIS; CELL CULTURE; CELL NUCLEUS; EPITHELIUM CELL; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

APOPTOSIS; CELL NUCLEUS; CELLS, CULTURED; EPITHELIAL CELLS; HELA CELLS; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; POLY I-C; RIBONUCLEOPROTEINS; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TOLL-LIKE RECEPTOR 3;

EID: 84908663367     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12432     Document Type: Article

References (45)

1. Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG. Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci 2006; 43:203-248.
2. Routsias JG, Kyriakidis N, Latreille M, Tzioufas AG. RNA recognition motif (RRM) of La/SSB: the bridge for interparticle spreading of autoimmune response to U1-RNP. Mol Med 2010; 16:19-26.
3. Yiannaki E, Vlachoyiannopoulos PG, Manoussakis MN etal. Study of antibody and T cell responses in rabbits immunized with synthetic human B cell epitope analogues of La (SSB) autoantigen. Clin Exp Immunol 2000; 121:551-556.
4. Tengner P, Halse AK, Haga HJ, Jonsson R, Wahren-Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren's syndrome. Arthritis Rheum 1998; 41:2238-2248.
5. Tzioufas AG, Hantoumi I, Polihronis M, Xanthou G, Moutsopoulos HM. Autoantibodies to La/SSB in patients with primary Sjogren's syndrome (pSS) are associated with upregulation of La/SSB mRNA in minor salivary gland biopsies (MSGs). J Autoimmun 1999; 13:429-434.
6. Manoussakis MN, Spachidou MP, Maratheftis CI. Salivary epithelial cells from Sjogren's syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation. J Autoimmun 2010; 35:212-218.
7. Spachidou MP, Bourazopoulou E, Maratheftis CI etal. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol 2007; 147:497-503.
8. Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. J Autoimmun 2012; 39:4-8.
9. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
10. Espinosa A, Dardalhon V, Brauner S etal. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009; 206:1661-1671.
11. Yang K, Shi HX, Liu XY etal. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 2009; 182:3782-3792.
12. Rhodes DA, Ihrke G, Reinicke AT etal. The 52000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology 2002; 106:246-256.
13. Strandberg L, Ambrosi A, Espinosa A etal. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008; 28:220-231.
14. Dimitriou ID, Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells. Eur J Oral Sci 2002; 110:21-30.
15. Vitali C, Bombardieri S, Jonsson R etal. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 2001; 25:402-408.
17. Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum 2005; 52:1517-1521.
18. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010; 34:400-407.
19. Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. J Immunol 2001; 166:3107-3113.
20. Jin JO, Shinohara Y, Yu Q. Innate immune signaling induces interleukin-7 production from salivary gland cells and accelerates the development of primary Sjogren's syndrome in a mouse model. PLOS ONE 2013; 8:e77605.
21. Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 2012; 39:77-82.
22. Espinosa A, Zhou W, Ek M etal. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006; 176:6277-6285.
23. Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006; 339:415-421.
24. Espinosa A, Oke V, Elfving A, Nyberg F, Covacu R, Wahren-Herlenius M. The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. Exp Cell Res 2008; 314:3605-3613.
25. Moutsopoulos HM. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994; 72:162-165.
26. Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009; 38:42-47.
27. Nandula SR, Scindia YM, Dey P, Bagavant H, Deshmukh US. Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjogren's syndrome-like disease. Oral Dis 2011; 17:801-807.
28. Nandula SR, Dey P, Corbin KL, Nunemaker CS, Bagavant H, Deshmukh US. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med 2013; 42:66-72.
29. Jimenez F, Aiba-Masago S, Al Hashimi I etal. Activated caspase 3 and cleaved poly(ADP-ribose) polymerase in salivary epithelium suggest a pathogenetic mechanism for Sjogren's syndrome. Rheumatology (Oxf) 2002; 41:338-342.
30. Kong L, Ogawa N, McGuff HS etal. Bcl-2 family expression in salivary glands from patients with primary Sjogren's syndrome: involvement of Bax in salivary gland destruction. Clin Immunol Immunopathol 1998; 88:133-141.
31. Kong L, Ogawa N, Nakabayashi T etal. Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 1997; 40:87-97.
32. Manganelli P, Quaini F, Andreoli AM etal. Quantitative analysis of apoptosis and bcl-2 in Sjogren's syndrome. J Rheumatol 1997; 24:1552-1557.
33. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med 1995; 181:1557-1561.
34. Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren's syndrome. Scand J Immunol 2002; 56:456-469.
35. Okuma A, Hoshino K, Ohba T etal. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjogren's syndrome-like autoimmune disease. Immunity 2013; 38:450-460.
36. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301:5-8.
37. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010; 35:225-231.
38. Bave U, Nordmark G, Lovgren T etal. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52:1185-1195.
39. Gottenberg JE, Cagnard N, Lucchesi C etal. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103:2770-2775.
40. Vogelsang P, Brun JG, Oijordsbakken G, Skarstein K, Jonsson R, Appel S. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 2010; 69:1235-1238.
41. Hall JC, Casciola-Rosen L, Berger AE etal. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci USA 2012; 109:17609-17614.
42. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 2000; 165:3519-3526.
43. Kelly KM, Zhuang H, Nacionales DC etal. 'Endogenous adjuvant' activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum 2006; 54:1557-1567.
44. Laurie GW, Glass JD, Ogle RA, Stone CM, Sluss JR, Chen L. 'BM180': a novel basement membrane protein with a role in stimulus-secretion coupling by lacrimal acinar cells. Am J Physiol 1996; 270 (6 Pt 1):C1743-1750.
45. Negishi H, Osawa T, Ogami K etal. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci USA 2008; 105:20446-20451.